HOME >> BIOLOGY >> NEWS
DFG to fund nine clinical trials

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) has announced funding for nine clinical trials in a joint programme established in 2003 by the DFG and the German Federal Ministry of Education and Research (BMBF). This decision was reached by the DFG's Joint Committee at its meeting on 2 September 2005. The programme's objective is the long-term sustainable improvement of patient-oriented clinical research in Germany. This will foster the expertise of German university hospitals in terms of planning and carrying out clinical trials, helping to ensure its establishment on a broad basis.

Whereas the DFG will primarily fund diagnostic and non-pharmacological therapeutic procedures, the BMBF, which is funding eight additional clinical trials, will focus more on pharmacological therapeutic procedures. The DFG and the BMBF will each initially provide annual programme funding of 5 million until 2008.

The nine clinical trials to be funded by the DFG are as follows:

The clinical trial Spiral CT Scanning for the Early Detection of Lung Cancer; Randomized Controlled Screening Trial of Multidetector Spiral CT Scanning in Germany" at the German Cancer Research Center in Heidelberg is part of an international study being carried out in Europe. Its objective is to improve the assessment of the benefits of annual screening by means of multidetector spiral CT, or MSCT, for patients with an increased risk of lung cancer. In Germany over 42,000 people are diagnosed with lung cancer each year, primarily smokers.
(Total funding: 651,911. Coordinator: Prof. Nikolaus Becker, German Cancer Research Center, Heidelberg)

Patients with cirrhosis of the liver tend to suffer from vasodilation, such as varicose veins in the oesophagus and the stomach. The most frequent cause of death is blood vessel haemorrhaging. However, conventional measures for controlling this risk of variceal bleeding also represent numerous risks. The clinical
'"/>

Contact: Dr. Eva-Maria Streier
em.streier@dfg.de
49-228-885-2250
Deutsche Forschungsgemeinschaft
13-Sep-2005


Page: 1 2 3 4

Related biology news :

1. Preclinical study links gene to brain aneurysm formation
2. Gene variant is associated with brain anatomy, clinical course of ADHD
3. New joint replacement material developed at MGH put to first clinical use
4. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
5. From clinical cancer research: rethinking therapeutic cancer vaccine trials
6. Manganese levels increase in scrapie-infected sheep before clinical symptoms develop
7. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
8. Alzheimers drug based on Purdue -- designed inhibitor begins clinical trials
9. UT Southwestern joins national clinical trial to uncover long-term effects of West Nile virus
10. BDSI announces positive phase III clinical trial results
11. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: DFG fund nine clinical trials

(Date:6/17/2013)... On June 6, professors in Wayne State ... National Science Foundation-funded (NSF) Research Experience for Undergraduates ... an opportunity to do cutting-edge research in astrophysics, ... According to Alexey Petrov, Ph.D., professor of physics ... principal investigator and program director of the grant, ...
(Date:6/17/2013)... a sugar alcohol produced by fungi, bacteria, and algae, ... The sweetener is also used in the medical field ... to flush out excess fluids and used during surgery ... ease the passage of other drugs. , Now Profs. ... Department of Molecular Microbiology and Biotechnology and the Sagol ...
(Date:6/17/2013)... method of mining shale gas, is widespread across Pennsylvania, ... New research in the Annals of the New ... to biodiversity including pollution from toxic chemicals, the building ... , "Shale gas has engendered a great deal of ... but effects on biological diversity and resources have scarcely ...
Breaking Biology News(10 mins):Wayne State welcomes undergraduates from around the US for physics research experience 2Artificial sweetener a potential treatment for Parkinson's disease 2
(Date:6/17/2013)... , June 17, 2013 /PRNewswire-iReach/ -- The ... Bob Riedford , President/Founder of Riedford Management, Inc. to its ... as a member of the Chamber,s Board of Advisors," said ... "This is one of the most prestigious positions to hold ... and experience our new board members will contribute." ...
(Date:6/16/2013)... This training is ideal for those who ... the software industry or those who want to explore Agile ... , The topics that will be covered in the 1-day ... meetings, scrum artifacts, and scrum simulation (optional). , The ... CO June 28, 2013 , Click here to register for ...
(Date:6/14/2013)... , June 14, 2013  Royalty Pharma notes today,s ... that it intends to explore a sale of the Company. ... that offers shareholders no certainty that a deal will ever be ... vote today AGAINST all four resolutions up for ... to preserve Royalty Pharma,s formal offer for Elan. In ...
(Date:6/14/2013)... The OpenClinica Global Conference is being ... with Formedix CEO, Mark Wheeldon presenting as part of ... deeper insight into the future developments at OpenClinica and ... to develop innovative solutions. , The conference program will ... hear real-life case studies and discover more about best ...
Breaking Biology Technology:Raleigh Chamber Names Bob Riedford to Board of Advisors 2Affordable Scrum Trainings in Denver, CO – 8 PDUs (June 28, 2013) by Conscires Agile Practices 2Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 2Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 3Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 4Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 5Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 6Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 7Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 8Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 9Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 10Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 11Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston 2Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston 3
Cached News: